UPDATE 1-AmerisourceBergen profit beats as generic drug prices stabilize

(Adds details on quarter, forecast, analysts' estimates)

Feb 6 (Reuters) - U.S. drug distributor AmerisourceBergen Corp's quarterly profit beat analysts' expectations as generic drug prices showed signs of stabilization.

"In the first quarter of the fiscal year, we saw further market, pricing and competitive stability," Chief Executive Steven Collis said in a statement.

AmerisourceBergen raised its adjusted earnings forecast for fiscal 2018 to $6.45 to $6.65 per share from $5.90 to $6.15 to account for the benefits from the recent changes to U.S. tax laws.

The drug wholesaler recorded a $587.6 million tax benefit in the latest quarter, which helped profit more than triple to $861.9 million, or $3.90 per share, from $247.2 million, or $1.11 per share, a year earlier.

Excluding items, the company earned $1.55 per share in the quarter ended Dec. 31.

Revenue rose 6 percent to $40.47 billion.

Analysts on average were expecting adjusted earnings of $1.35 per share on revenue of $40.50 billion, according to Thomson Reuters I/B/E/S. (Reporting by Tamara Mathias and Anuron Kumar Mitra in Bengaluru; Editing by Savio D'Souza)